An Overview of the U.S. Biosimilars Market

Oct. 21, 2011 - PRLog -- Contact:
Britni Myers
Frost & Sullivan               
+1.210.477.8481               
britni.myers@frost.com

Press Release


An Overview of the U.S. Biosimilars Market

Frost & Sullivan hosts complimentary webinar discussing the potential benefits and risks of an untapped market

MOUNTAIN VIEW, CA
WHEN:      Thursday, Oct. 27, 2011 at 1 p.m. EDT
LOCATION:   Online, with free registration
SPEAKERS:    Debbie Toscano, Senior Industry Analyst for Frost & Sullivan’s Pharmaceutical & Biotechnology practice

The U.S. biosimilars market is on the verge of transitioning from future plan to reality.  Numerous biosimilars, or follow-on biologics, have already been successfully launched in many countries outside the U.S.  Lower cost biosimilar versions of widely used biologic therapies, such as monoclonal antibodies and hormones, are now eagerly awaited in the U.S. where they are expected to significantly impact healthcare costs.  However, uncertainty surrounding pending legislation currently under debate could considerably influence the true potential of this market.  This briefing will discuss how the regulatory authorities define a biosimilar, the current status of legislation governing the approval of biosimilars, and the potential challenges and benefits that will shape the ultimate potential of this technology-enabled market.

Why you should attend:
•   Learn how biosimilars differ from conventional generic drugs
•   Learn the issues involved in governing approval of biosimilars in the U.S.
•   Understand the risks and potential benefits of this market
•   Identify the factors with the potential to impact the uptake of biosimilars

This briefing will benefit physicians, pharmaceutical industry market participants, investors, pharmacy benefit managers and other healthcare community members who desire an in-depth analysis of the potential for biosimilars in the U.S. market.

Supporting Quotes
“The market for biosimilars in the U.S. holds great potential, however, there is still a great amount of uncertainty,” said Frost & Sullivan Senior Industry Analyst Debbie Toscano.  “This could spell the difference between success and failure for those with the technological and commercial capabilities to introduce follow-on biologics to the U.S. market.”

Supporting Resources
For more information about Frost & Sullivan’s Healthcare practice, please visit: http://www.frost.com/healthcare

Registration
•   To attend the briefing, email britni.myers@frost.com your full name, job title, company name, company telephone number, company email address and Web site, city, state and country.
•   Receive a recorded version of the briefing anytime by submitting the aforementioned contact details.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

# # #

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.